Researchers have achieved a significant breakthrough in identifying the primary cause and potential treatment for preeclampsia, a severe pregnancy complication. Experts pinpointed a toxic protein named cis P-tau in the blood and placenta of individuals with preeclampsia. The study describes cis P-tau as a pivotal circulating instigator of preeclampsia. An antibody developed in 2012 to target only the toxic protein while leaving its healthy counterpart unscathed is currently undergoing clinical trials in human patients suffering from traumatic brain injury and Alzheimer's Disease. The antibody has shown promising results in animal models and human cell cultures in treating the brain conditions. Upon testing this antibody in mice, the researchers found the all symptoms associated with preeclampsia were corrected.

The tragic death of American track and field champion Tori Bowie earlier this year put the spotlight on preeclampsia, which disproportionately impacts Black and Hispanic women.

Researchers from Western and Brown University have made groundbreaking progress towards identifying the root cause and potential therapy for preeclampsia.